Medicare obesity drugs coverage will begin July 1 through a new federal pilot program. The change gives some Medicare Part D beneficiaries access to select GLP-1 medications used for weight management.
Medicare Obesity Drugs Coverage Starts July 1
The Centers for Medicare & Medicaid Services will launch the Medicare GLP-1 Bridge on July 1. The short-term program will run through Dec. 31, 2027.
For the first time, eligible Medicare patients may receive certain obesity medications for weight management. The program will offer a $50 copay for a monthly supply.
The program is separate from regular Medicare Part D coverage. That means the $50 copay will not count toward a beneficiary’s Part D out-of-pocket costs. Low-income subsidy assistance also will not apply to the bridge copay.
CMS says the program will use a central processor to handle prior authorization, claims and pharmacy payments.
Which GLP-1 Drugs Are Included
The covered medications include all formulations of Wegovy and Foundayo, along with the KwikPen version of Zepbound. Other Zepbound formulations are not included in the bridge program.
GLP-1 drugs work by helping regulate appetite and blood sugar signals. They have become widely known for treating obesity and Type 2 diabetes.
Some GLP-1 drugs are already covered by Medicare Part D when prescribed for approved conditions such as Type 2 diabetes. The new bridge program focuses on use for reducing excess body weight and maintaining weight reduction.
CMS says patients who use GLP-1 drugs for conditions already covered by Part D should continue getting them through their Part D plan.
Who May Qualify
Not every Medicare beneficiary will qualify. Patients must have Medicare Part D coverage through an eligible plan and meet clinical requirements.
A provider must submit a prior authorization request. The prescription must be used for weight management along with ongoing lifestyle changes, including nutrition and physical activity.
Patients may qualify with a body mass index, or BMI, of 35 or higher. Some patients may qualify with a BMI of 30 or higher if they also have certain health conditions, including uncontrolled high blood pressure, chronic kidney disease or heart failure with preserved ejection fraction.
Patients may also qualify with a BMI of 27 or higher if they have prediabetes, a previous heart attack, a previous stroke or symptomatic peripheral artery disease.
Prior authorization requests will not be accepted before July 1.
Why the Change Matters
The move marks a major shift in how Medicare treats obesity care. Federal law has long limited coverage for drugs used only for weight loss.
The new pilot program could reduce costs for eligible patients who might otherwise pay hundreds or more than $1,000 per month. It also gives Medicare time to gather more information about GLP-1 use, costs and health outcomes.
Doctors still urge patients to review risks and benefits before starting treatment. GLP-1 drugs can cause side effects, and older adults may need closer monitoring for nutrition, digestion and muscle loss.
For families across Texas and the country, the change could make obesity treatment more accessible. Eligible patients should speak with their doctor and check official Medicare information before July 1.